Phenomic AI
Phenomic AI is a biotech company using an ML-powered single-cell transcriptomics platform (scTx®) to discover therapeutic targets and antibody programs for stroma-rich solid tumors, monetized through strategic licensing and co-development partnerships with large pharmaceutical companies.
- Company typePrivate
- Founded2020
- HeadquartersWaltham, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Phenomic AI does
Phenomic AI is a privately held biotechnology company that develops an ML-powered single-cell transcriptomics platform, branded as scTx®, to discover and optimize therapeutics for stroma-rich solid tumors. The platform processes imaging, RNA sequencing, and spatial transcriptomics data to interrogate cell type and target expression profiles in human cancer and normal tissue samples, as well as in disease-relevant experimental systems including human tumor explants and animal models. By focusing on tumor stroma rather than traditional tumor-associated antigens, the company targets an underserved biology niche in cancers with historically poor outcomes, including colorectal, pancreatic, and breast cancers. Its lead internal asset is a CD3 engager program, which has advanced to development candidate stage and is designed to overcome limitations of conventional tumor-associated antigen targeting.
Phenomic AI operates a platform-plus-programs business model: it monetizes the scTx platform primarily through strategic research collaborations and licensing agreements with large pharmaceutical companies, generating revenue from upfront payments, research funding, development milestones, and potential commercialization royalties. The company's GTM motion is enterprise field sales to pharmaceutical and biotechnology counterparties, with named partners including Boehringer Ingelheim under a deal headline-valued at over $509 million (announced November 2023) and Astellas Pharma through Xyphos Biosciences under a strategic research collaboration announced November 2023. The company's Scientific Advisory Board, anchored by Nobel Laureate James Allison and Padmanee Sharma, and its senior team, including CEO Girish Aakalu (formerly CBO at Genocea), CTO Sam Cooper (co-founder), and CSO Mike Briskin, support partner-facing credibility and scientific execution.
Phenomic AI firmographics
Firmographics- Name
- Phenomic AI
- Legal name
- Phenomic AI Inc.
- Website
- https://phenomic.ai
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Phenomic AI is a biotech company using an ML-powered single-cell transcriptomics platform (scTx®) to discover therapeutic targets and antibody programs for stroma-rich solid tumors, monetized through strategic licensing and co-development partnerships with large pharmaceutical companies.
- Ownership category
- akta.pro rank
Phenomic AI industry classification
Industry- Product category
- Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
- akta.pro secondary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where Phenomic AI is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Phenomic AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Research Collaborations: Revenue generated through strategic partnerships with pharmaceutical companies involving upfront payments, research funding, development milestones, and potential commercialization royalties. Examples include the Boehringer Ingelheim ($509M potential) and Astellas/Xyphos Biosciences collaborations.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels2 records
Phenomic AI product offering
Product offeringCore offering
Phenomic AI develops and operates the scTx® platform, an ML-powered single-cell transcriptomics system that processes imaging, RNA sequencing, and spatial transcriptomics data to identify novel drug targets and therapeutic approaches for solid tumors. The company also advances internal therapeutic programs, with a lead CD3 engager program, and monetizes its discovery engine through strategic research collaborations and licensing agreements with pharmaceutical companies.
Product overview
Phenomic AI operates as a biotech company with a platform-plus-programs architecture. The core technology is the scTx® single-cell transcriptomics platform, an ML-powered system that interrogates single-cell RNA data at scale using imaging, RNA sequencing, and spatial transcriptomics to understand cell interactions in solid tumors. This platform drives the company's therapeutic discovery engine, with the lead asset being a CD3 engager program currently at development candidate stage, focused on stroma-rich solid tumors.
Differentiator
Problem solved
Functional benefit
Products and services
- scTx® Single-Cell Transcriptomics Platform An AI/ML-powered platform that interrogates single-cell RNA data at scale using imaging, RNA sequencing, and spatial transcriptomics to understand cell type and target expression profiles in human cancer and normal tissue samples, as well as disease-relevant experimental systems such as human tumor explants and animal models. Licensed and used by pharmaceutical partners to discover novel, high-impact, druggable targets in solid tumors.
- CD3 Engager Program A CD3 engager therapeutic utilizing a novel targeting approach identified by the scTx platform, designed to overcome limitations of traditional tumor-associated antigens. Currently at development candidate stage with results in colorectal, pancreatic, and breast cancers; advanced through co-development and licensing arrangements with pharmaceutical partners.
Companies that use Phenomic AI
Customer profileNamed customers2 records
Segments1 record
Ideal customer profiles1 record
Phenomic AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature1 record
Phenomic AI partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered flagship.
- Astellas Pharma / Xyphos BiosciencesflagshipStrategic research collaboration to explore antibodies developed by Phenomic directed at novel tumor stroma targets identified using the scTx platform. The work aims to enhance cell therapy approaches for solid tumor treatment. Terms were not disclosed.
- Boehringer IngelheimflagshipStrategic collaboration and licensing agreement to discover targets important in stroma-rich cancers. The partnership leverages Phenomic's scTx single-cell transcriptomics platform to identify novel targets and enhance Boehringer's efforts to develop first-in-class medicines for cancer treatment. Deal valued at over $509 million including upfront, research, and development milestones.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Phenomic AI competitors and assessment
Company assessmentEmerging players
- Lantern Pharma: AI-driven oncology drug development company using ML and genomic data to identify and repurpose cancer therapies; comparable as a smaller AI-oncology player, though focused on later-stage drug development rather than Phenomic's target-discovery stage.
Direct peers
- Insitro: ML-enabled drug discovery platform combining induced pluripotent stem cell biology, high-throughput biology, and machine learning to discover therapeutics; comparable as a platform-plus-pipeline AI biotech with significant infrastructure investment.
- Atomwise: AI-driven small molecule drug discovery company using convolutional neural networks to predict binding and identify novel compounds; comparable as a venture-stage AI drug discovery company partnering with large pharmas, though focused on small molecules vs. Phenomic's biologics.
- Exscientia: AI-driven pharma company using AI/ML to design and develop novel drug candidates across multiple therapeutic areas, including oncology; comparable as a publicly-traded AI drug discovery company pursuing platform-partnership and internal asset strategies.
- Recursion Pharmaceuticals: AI/ML-driven drug discovery company using high-dimensional phenotypic data and automated wet-lab experimentation to identify novel therapeutics, directly comparable to Phenomic's ML + biology convergence approach for target discovery in oncology and beyond.
- BenevolentAI: AI-driven drug discovery company combining machine learning, computational biology, and biomedical knowledge graphs to identify novel targets and therapies; comparable in deploying ML to identify targets from complex biological data (a former Phenomic bioinformatician came from BenevolentAI).
- Generate Biomedicines: Generative AI biology platform for designing novel protein therapeutics including antibodies; comparable in applying AI to discover and design biologics such as the CD3 engagers Phenomic is developing.
- Cellarity: Single-cell-driven drug discovery company founded by Flagship Pioneering using phenotypic cellular behavior at single-cell resolution to discover therapeutics; highly comparable technology approach to Phenomic's scTx platform.
Broad incumbents
- Schrödinger: Computational drug discovery platform combining physics-based simulation, ML, and a SaaS-style platform serving pharma and biotech customers; broader portfolio than Phenomic but comparable in deploying computational methods for novel target and molecule identification.
- AbCellera: Antibody discovery platform combining high-throughput single-cell screening, ML, and engineering to discover antibody therapeutics; comparable for the antibody/biologics discovery and pharma-partnership model that Phenomic uses for CD3 engagers.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Phenomic AI social profiles
Digital presencePhenomic AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phenomic AI leadership team
Management profileNumber of profiles
Profiles5 records
Phenomic AI funding detail
Funding detailFunding overview
Funding rounds5 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phenomic AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phenomic AI
What does Phenomic AI do?
Phenomic AI develops and operates the scTx® platform, an ML-powered single-cell transcriptomics system that processes imaging, RNA sequencing, and spatial transcriptomics data to identify novel drug targets and therapeutic approaches for solid tumors. The company also advances internal therapeutic programs, with a lead CD3 engager program, and monetizes its discovery engine through strategic research collaborations and licensing agreements with pharmaceutical companies.
Is Phenomic AI a public or private company?
Phenomic AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phenomic AI founded?
Phenomic AI was founded in 2020. It employs 11 to 50 people.
Where is Phenomic AI based?
Phenomic AI is headquartered in Waltham, United States, in the North America region.
How does Phenomic AI make money?
One revenue line is on record: strategic Research Collaborations.
Who are Phenomic AI's main competitors?
Lantern Pharma is listed as an emerging player. Direct peers are Insitro, Atomwise, Exscientia, Recursion Pharmaceuticals, BenevolentAI, Generate Biomedicines and Cellarity. Broad incumbents are Schrödinger and AbCellera.
Does Phenomic AI have an API?
No public API is recorded for Phenomic AI.
What industry is Phenomic AI in?
Phenomic AI's product category is Drug Discovery Platform. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2836.